ASCO 2021 | CheckMate 238: nivolumab versus ipilimumab in stage III melanoma

James Larkin, PhD, FRCP, The Royal Marsden NHS Foundation Trust, London, UK, reports on the Phase III CheckMate 238 trial (NCT02388906) of nivolumab versus ipilimumab in patients with stage III melanoma. Despite nivolumab and ipilimumab having similar overall survival (OS) rates, nivolumab is superior in terms of relapse-free survival. Dr Larkin additionally discusses nivolumab in patients with in-transit metastases, where outcomes for the subset of patients are consistent with the wider cohort. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.